98%
921
2 minutes
20
Aims: Type 2 diabetes (T2D) related cognitive impairment links to comorbid and modifiable olfactory dysfunction; however, the efficacy of olfactory training (OT) to mitigate cognitive decline specifically in these patients with mild cognitive impairment (MCI) remains unestablished. This study aimed to determine whether OT alleviates cognitive decline in this population.
Materials And Methods: In this 16-week, open-label trial, 60 T2D participants with MCI were randomly assigned (1:1) to OT or routine care (control). The OT group performed twice-daily 6-minute exposure to six odorants (rose, eucalyptus, lemon, clove, coffee, and cinnamon), with adherence monitored remotely. The primary outcome was the change in Montreal Cognitive Assessment (MoCA) score. Secondary outcomes included: (1) other neuropsychological assessments, (2) olfactory tests, (3) structural and odour-induced functional magnetic resonance imaging, and (4) metabolic parameters.
Results: OT significantly improved global cognition, as demonstrated by greater score increases in MoCA (OT: Δ + 1.9 vs. control: Δ + 0.4, p = 0.001, η_p = 0.190, 95% CI [0.04, 0.35]) compared to controls. Domain-specific enhancements were observed in visuospatial constructional, language, and executive function. Concurrently, OT elevated overall olfactory performance. Neuroimaging revealed parallel neural alterations, with volume increases in hippocampal subfields and prefrontal hypoactivation during tasks. Critically, mediation analysis showed olfactory enhancement (Δolfactory total score) mediated global cognitive improvement (ΔMoCA). No significant metabolic differences emerged between groups.
Conclusions: A 16-week OT regimen improves global and domain-specific cognition for MCI in T2D, alongside olfactory and neuroimaging enhancements. These findings support OT as a low-cost, home-based strategy for cognitive preservation in this high-risk population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/dom.70103 | DOI Listing |
Ann Med
December 2025
School of Acupuncture-Moxibustion and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background: To review the biological functions of ergothioneine (ERGO), its correlation with plasma levels in cognitive frailty, and research progress in treating frailty and cognitive impairment, with the aim of providing a reference for ERGO application in cognitive frailty treatment.
Methods: A comprehensive review of existing literature on ERGO's chemical structure, sources, antioxidant and anti-inflammatory effects, and its role in cognitive frailty was conducted. Clinical trial data and metabolomic studies were also analyzed to understand ERGO's therapeutic potential.
Disabil Rehabil
September 2025
Occupational Performance Network, Sydney, Australia.
Purpose: Initial studies identified the Perceive, Recall, Plan and Perform Assessment (PRPP-A) as a cognitive assessment with potential for culturally safe use with Aboriginal and Torres Strait Islander peoples with neurocognitive impairments in the Northern Territory of Australia. This study examines construct and concurrent validity of the PRPP-A.
Methods: Data were collected from a medical record review.
J Atten Disord
September 2025
Universidad Nacional Autónoma de México, Mexico.
Objective: Susceptibility to visual illusions is a consequence of the adaptation of the visual system, however, their perception or lack of it reflects differences in more general, global cognitive processes. Few studies have focussed on the susceptibility of individuals with attention-deficit/hyperactivity disorder (ADHD), even though visual impairment and percept differences have been thoroughly documented.
Method: The present study evaluated 75 children (ages 6.
Mol Psychiatry
September 2025
Institute of Neurology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054, China.
Alzheimer's disease (AD), a leading cause of dementia, represents a critical unmet global medical need. While the precise mechanisms underlying AD pathogenesis remain elusive, increasing evidence underscores the pivotal role of neuroinflammation in driving cognitive impairment. N6-methyladenosine (m6A), an epigenetic modification regulating RNA metabolism, has been found to be dysregulated in AD.
View Article and Find Full Text PDFGeroscience
September 2025
Department of Biological Sciences, College of Natural Sciences, Kangwon National University, Kangwon, 24341, Republic of Korea.
Alzheimer's disease (AD) represents a growing global health burden, underscoring the urgent need for reliable diagnostic and prognostic biomarkers. Although several disease-modifying treatments have recently become available, their effects remain limited, as they primarily delay rather than halt disease progression. Thus, the early and accurate identification of individuals at elevated risk for conversion to AD dementia is crucial to maximize the effectiveness of these therapies and to facilitate timely intervention strategies.
View Article and Find Full Text PDF